Neurointervention.  2020 Mar;15(1):52-54. 10.5469/neuroint.2019.00297.

Analysis of the Occurrence of Major Hemorrhagic Incidents in Patients with Low-Dose Aspirin Usage in Korean Populations – Does Low-Dose Aspirin Really Increase the Risk of Bleeding?

• Kim TG
• Kim SH

• KMID: 2502085
• DOI: http://doi.org/10.5469/neuroint.2019.00297

Reference

1. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849–1860.

2. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive services task force. Ann Intern Med. 2016; 164:826–835.

3. De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012; 307:2286–2294.

4. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PloS One. 2016; 11:e0160046.

5. García-Rodríguez LA, Gaist D, Morton J, Cookson C, González- Pérez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology. 2013; 81:566–574.

6. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne risk factor study (merfs) group. Stroke. 1996; 27:2020–2025.